东亚药业(605177.SH)发布前三季度业绩，归母净亏损7241万元

Core Viewpoint - East Asia Pharmaceutical (605177.SH) reported a significant decline in revenue and incurred losses in the first three quarters of 2025 [1] Financial Performance - The company achieved a revenue of 596 million yuan in the first three quarters, representing a year-on-year decrease of 38.08% [1] - The net profit attributable to the parent company was a loss of 72.41 million yuan [1] - The non-recurring net profit also showed a loss of 81.98 million yuan [1] - Basic earnings per share were reported at -0.63 yuan [1]